‹ Back
Tirzepatide
Why it is for you
Tirzepatide suits a root-cause picture of insulin resistance: a thick waist, fatty liver, high triglycerides, rising fasting sugar or prediabetes, and a hunger drive that keeps winning. It fits people who need a large, steady drop in body fat and want a well-known, predictable signal. It pairs well with a high protein diet and resistance training to keep muscle, with MOTS-c or 5-Amino-1MQ on the cellular energy side, and with BPC-157 when the gut lining needs repair first. It is not paired with another GLP-1 product, because they act on the same receptor.
Sources
Read the original sources
- LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. (Coskun · 2018 · Abstract; full methods not assumed · checked 2026-10-13)
- A contemporary rationale for GIP receptor agonism in obesity, Samms 2025, Diabetes (Abstract · checked 2026-10-13)
- Tirzepatide: unimolecular polypharmacology for obesity, 2025, Endocrinology: News, Opinions, Training (Russia) (Summary · checked 2026-10-13)